8-K filing — Viking Therapeutics, Inc. (VKTX)
Filed: 2026-10-28 AccNo: 0001193125-26-436145 Size: 524 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Viking Therapeutics Reports Third Quarter 2026 Financial Results
Viking Therapeutics announced its financial results for the third quarter and nine months ended September 30, 2026, alongside updates on its clinical pipeline.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Viking Therapeutics, Inc. has scheduled the release of its financial results for the third quarter of 2026 for October 28, 2026, followed by a conference call.
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.